Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2025-03-04 00:00:00 ET · period of report 2025-02-28 · accession 0000950170-25-032309 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-03-04 | 2025-02-28 | KPTI | Poulton Stuart | EVP, Chief Development Off | A - Grant | $0.00 | +9,583 | 31.0K | +45% | $0 |
| DM | 2025-03-04 | 2025-02-28 | KPTI | Poulton Stuart | EVP, Chief Development Off | A - Grant | $0.00 | +19.2K | 10.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-28 | A | A | 5,000 | $0.00 | 26,379 | D | — | — | (F2) Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. (F1) Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026. |
| 2 | Common | Common Stock | 2025-02-28 | A | A | 4,583 | $0.00 | 30,962 | D | — | — | (F3) Represents the award of RSUs pursuant to the 2022 Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in two equal annual installments beginning February 28, 2026. (F2) Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. |
| 3 | Derivative | Stock Option (right to buy) | 2025-02-28 | A | A | 9,166 | $0.00 | 9,166 | D | $7.95 · — to 2035-02-27 | 9,166 Common Stock | (F2) Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. (F4) This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
| 4 | Derivative | Stock Option (right to buy) | 2025-02-28 | A | A | 10,000 | $0.00 | 10,000 | D | $7.95 · — to 2035-02-27 | 10,000 Common Stock | (F2) Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. (F4) This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter. |